vs
Side-by-side financial comparison of EQUITY BANCSHARES INC (EQBK) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $63.5M, roughly 1.4× EQUITY BANCSHARES INC). On growth, EQUITY BANCSHARES INC posted the faster year-over-year revenue change (28.4% vs 17.7%). EQUITY BANCSHARES INC produced more free cash flow last quarter ($38.1M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.6%).
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
EQBK vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $63.5M | $86.8M |
| Net Profit | $22.1M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 41.7% | -84.7% |
| Net Margin | 34.8% | — |
| Revenue YoY | 28.4% | 17.7% |
| Net Profit YoY | 30.0% | — |
| EPS (diluted) | $1.07 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $63.5M | $86.8M | ||
| Q3 25 | $18.0M | $67.5M | ||
| Q2 25 | $58.4M | $60.0M | ||
| Q1 25 | $60.6M | $49.3M | ||
| Q4 24 | $58.3M | $73.7M | ||
| Q3 24 | $55.3M | $58.6M | ||
| Q2 24 | $55.4M | $31.1M | ||
| Q1 24 | $55.9M | $715.0K |
| Q4 25 | $22.1M | — | ||
| Q3 25 | $-29.7M | $-91.3M | ||
| Q2 25 | $15.3M | $-111.7M | ||
| Q1 25 | $15.0M | $-116.2M | ||
| Q4 24 | $17.0M | — | ||
| Q3 24 | $19.9M | $-83.5M | ||
| Q2 24 | $11.7M | $-97.1M | ||
| Q1 24 | $14.1M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 41.7% | -84.7% | ||
| Q3 25 | -207.2% | -140.7% | ||
| Q2 25 | 31.5% | -189.8% | ||
| Q1 25 | 31.1% | -245.8% | ||
| Q4 24 | 35.0% | -117.5% | ||
| Q3 24 | 43.1% | -152.1% | ||
| Q2 24 | 29.4% | -327.6% | ||
| Q1 24 | 31.8% | -16464.6% |
| Q4 25 | 34.8% | — | ||
| Q3 25 | -164.7% | -135.3% | ||
| Q2 25 | 26.1% | -186.2% | ||
| Q1 25 | 24.8% | -235.5% | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 35.9% | -142.7% | ||
| Q2 24 | 21.1% | -312.2% | ||
| Q1 24 | 25.2% | -15800.8% |
| Q4 25 | $1.07 | — | ||
| Q3 25 | $-1.55 | — | ||
| Q2 25 | $0.86 | $-0.33 | ||
| Q1 25 | $0.85 | $-0.36 | ||
| Q4 24 | $1.06 | $-0.24 | ||
| Q3 24 | $1.28 | $-0.28 | ||
| Q2 24 | $0.76 | $-0.34 | ||
| Q1 24 | $0.90 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $443.2M | — |
| Stockholders' EquityBook value | $732.1M | $698.6M |
| Total Assets | $6.4B | $913.2M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $443.2M | — | ||
| Q3 25 | $486.9M | — | ||
| Q2 25 | $448.4M | — | ||
| Q1 25 | $376.9M | — | ||
| Q4 24 | $312.8M | — | ||
| Q3 24 | $437.5M | — | ||
| Q2 24 | $391.7M | — | ||
| Q1 24 | $367.1M | — |
| Q4 25 | $732.1M | $698.6M | ||
| Q3 25 | $711.9M | $702.3M | ||
| Q2 25 | $635.6M | $698.5M | ||
| Q1 25 | $617.3M | $767.9M | ||
| Q4 24 | $592.9M | $710.4M | ||
| Q3 24 | $504.0M | $773.5M | ||
| Q2 24 | $461.4M | $768.5M | ||
| Q1 24 | $456.8M | $680.0M |
| Q4 25 | $6.4B | $913.2M | ||
| Q3 25 | $6.4B | $904.9M | ||
| Q2 25 | $5.4B | $907.4M | ||
| Q1 25 | $5.4B | $966.7M | ||
| Q4 24 | $5.3B | $910.4M | ||
| Q3 24 | $5.4B | $991.1M | ||
| Q2 24 | $5.2B | $964.3M | ||
| Q1 24 | $5.2B | $869.8M |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 0.85× | — | ||
| Q1 24 | 0.80× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $51.4M | $-52.6M |
| Free Cash FlowOCF − Capex | $38.1M | $-61.9M |
| FCF MarginFCF / Revenue | 60.0% | -71.3% |
| Capex IntensityCapex / Revenue | 20.9% | 10.7% |
| Cash ConversionOCF / Net Profit | 2.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | $88.8M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $51.4M | $-52.6M | ||
| Q3 25 | $8.5M | $-78.7M | ||
| Q2 25 | $28.3M | $-67.4M | ||
| Q1 25 | $21.7M | $-103.7M | ||
| Q4 24 | $73.8M | $-73.3M | ||
| Q3 24 | $23.5M | $-59.0M | ||
| Q2 24 | $16.0M | $-98.4M | ||
| Q1 24 | $12.6M | $-122.3M |
| Q4 25 | $38.1M | $-61.9M | ||
| Q3 25 | $4.5M | $-89.5M | ||
| Q2 25 | $26.0M | $-74.9M | ||
| Q1 25 | $20.2M | $-109.9M | ||
| Q4 24 | $65.4M | $-77.5M | ||
| Q3 24 | $19.7M | $-61.3M | ||
| Q2 24 | $15.2M | $-98.9M | ||
| Q1 24 | $10.6M | $-126.5M |
| Q4 25 | 60.0% | -71.3% | ||
| Q3 25 | 24.7% | -132.7% | ||
| Q2 25 | 44.5% | -124.9% | ||
| Q1 25 | 33.3% | -222.8% | ||
| Q4 24 | 112.1% | -105.1% | ||
| Q3 24 | 35.6% | -104.6% | ||
| Q2 24 | 27.4% | -317.9% | ||
| Q1 24 | 19.0% | -17685.3% |
| Q4 25 | 20.9% | 10.7% | ||
| Q3 25 | 22.3% | 16.1% | ||
| Q2 25 | 3.9% | 12.4% | ||
| Q1 25 | 2.4% | 12.6% | ||
| Q4 24 | 14.6% | 5.7% | ||
| Q3 24 | 6.8% | 3.9% | ||
| Q2 24 | 1.5% | 1.4% | ||
| Q1 24 | 3.6% | 583.4% |
| Q4 25 | 2.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 4.35× | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EQBK
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
